


Aimovig® (erenumab) Clinical Trials

By The Numbers

Aimovig® (erenumab) is the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine. It has been studied in several large, global, randomized, double-blind, placebo-controlled studies to assess its safety and efficacy in migraine prevention.



THE AIMOVIG CLINICAL TRIAL PROGRAM¹⁻⁴

- Over **3,000 adult migraine patients*** participated in Aimovig clinical studies
- **5 year** extension safety study is ongoing
- Safety profile of Aimovig was similar to placebo across the clinical trial program

STRIVE¹ Phase III Study

STRIVE (NCT02456740) is a **6-month** Phase III study evaluating the safety and efficacy of Aimovig 70mg and 140mg in people experiencing between four and 14 migraine days per month.**

121 clinical trial sites in **13** countries

Enrolled **955** patients with an average of **8.3** migraine days per month at baseline

PRIMARY ENDPOINT MET
-3.2 and **-3.7** migraine days per month with Aimovig at 70mg and 140mg doses respectively, **-1.8** migraine days per month for placebo (p<0.001 for both doses vs. placebo)

ARISE² Phase III Study

ARISE (NCT02483585) is a **3-month** Phase III study evaluating the safety and efficacy of Aimovig 70mg in people experiencing between four and 14 migraine days per month.***

76 clinical trial sites in **8** countries

Enrolled **577** patients with an average of **8** migraine days per month at baseline

PRIMARY ENDPOINT MET
-2.9 migraine days per month with Aimovig 70mg, **-1.8** migraine days per month for placebo (p<0.001 vs. placebo)

Chronic Migraine – Phase II Study³

The Pivotal Phase II (NCT02066415) is evaluating the safety and efficacy of Aimovig 70mg and 140mg in people experiencing 15 or more migraine days per month.***

69 clinical trial sites in **10** countries

Enrolled **667** people with an average of **18** migraine days per month at baseline

PRIMARY ENDPOINT MET
-6.6 migraine days per month with Aimovig at both doses (70mg and 140mg), **-4.2** migraine days per month for placebo (p<0.001 for both doses vs. placebo)

LIBERTY⁵ Phase IIIb Study: the first study to investigate a treatment targeting the CGRP pathway specifically in patients who had failed 2 to 4 prior preventive treatments

LIBERTY (NCT03096834) is a 12-week Phase IIIb study evaluating the safety and efficacy of Aimovig 140mg in people experiencing between four and 14 migraine days per month AND who failed 2-4 preventive migraine treatments due to lack of efficacy or intolerable side effects***

65 clinical trial sites in **16** countries

Enrolled **246** patients with an average of **9.3** migraine days per month at baseline

PRIMARY ENDPOINT MET
30.3% of those taking Aimovig had a reduction of at least 50% in monthly migraine days from baseline compared to **13.7%** of those taking placebo (p<0.001, odds ratio 2.73)

ALL SECONDARY ENDPOINTS MET INCLUDING
-1.76 migraine days per month with Aimovig at 140mg, **-0.15** migraine days per month for placebo (p=0.004 vs. placebo)

* Aged 18–65, experiencing 4 or more migraine days per month

** All endpoint assessments for STRIVE compared baseline to the last three months of the 6-month treatment phase.

*** All endpoint assessments for ARISE, the Phase II study and LIBERTY compared baseline to the last month of the 3-month treatment phases.

REFERENCES

1. Goadsby PJ et al. Trial of erenumab for episodic migraine. N Engl J Med. 2017 Nov 30;377(22):2123-2132.
2. Dodick DW et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 Jan 1;33(1):2418759786.
3. Tepper S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jun;16(6):425-434.
4. Data on file.
5. Reuter, U et al. Efficacy and safety of erenumab in episodic migraine patients with 2–4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study. Emerging science abstract presented at AAN, 24 April 2018, Los Angeles.